Stroke, Vol 23, 388-393, Copyright © 1992 by American Heart Association
D Russell, KP Madden, WM Clark and JA Zivin
BACKGROUND AND PURPOSE: The main aim of our study was to assess the
cerebrovascular thrombolytic efficacy of different tissue plasminogen
activator treatment protocols with Doppler ultrasound. METHODS: We occluded
one internal carotid artery in 48 New Zealand White rabbits with whole
blood emboli. Five minutes later the rabbits were assigned to receive one
of the following tissue plasminogen activator protocols: 1) intravenous
square-wave infusion in a total dose of 10 mg/kg, 2) intravenous constant
infusion in a total dose of 10 mg/kg, 3) intravenous square-wave infusion
in a total dose of 3 mg/kg, or 4) regional intra-arterial square-wave
infusion in a total dose of 3 mg/kg. Blood flow velocities in the internal
carotid arteries were continuously monitored during the study with Doppler
ultrasound. RESULTS: In all 12 animals treated with a 10-mg/kg square-wave
intravenous tissue plasminogen infusion, internal carotid artery blood flow
was reestablished within 2 hours (57.9 +/- 33.3 minutes) after the
initiation of treatment, whereas this was the case for only six (50%) of
the 12 animals treated with a constant 10-mg/kg intravenous tissue
plasminogen activator infusion (p less than 0.05, Fisher's exact test).
Internal carotid artery blood flow was restored within 2 hours (33.5 +/-
40.4 minutes) in all animals treated with a regional intra-arterial tissue
plasminogen infusion in a total dose of 3 mg/kg and in only three (50%) of
the six animals treated with the same dosage intravenously (p less than
0.05, signed rank test). CONCLUSIONS: The thrombolytic efficacy of tissue
plasminogen activator in the rabbit cerebral vasculature was superior when
the same intravenous dose was given as a square-wave rather than a constant
infusion and when the drug was given as a regional intra-arterial infusion
rather than intravenously.
ARTICLES
Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration
University of California, School of Medicine, Department of Neurosciences, La Jolla 92093-0624.
This article has been cited by other articles:
![]() |
P. A. Lapchak and J. A. Zivin Ebselen, a Seleno-Organic Antioxidant, Is Neuroprotective After Embolic Strokes in Rabbits: Synergism With Low-Dose Tissue Plasminogen Activator Stroke, August 1, 2003; 34(8): 2013 - 2018. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Lapchak, D. M. Araujo, D. Song, J. Wei, R. Purdy, and J. A. Zivin Effects of the Spin Trap Agent Disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-Oxide (Generic NXY-059) on Intracerebral Hemorrhage in a Rabbit Large Clot Embolic Stroke Model: Combination Studies With Tissue Plasminogen Activator Stroke, June 1, 2002; 33(6): 1665 - 1670. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Lapchak, D. M. Araujo, D. Song, and J. A. Zivin The Nonpeptide Glycoprotein IIb/IIIa Platelet Receptor Antagonist SM-20302 Reduces Tissue Plasminogen Activator-Induced Intracerebral Hemorrhage After Thromboembolic Stroke Stroke, January 1, 2002; 33(1): 147 - 152. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Lapchak, D. F. Chapman, and J. A. Zivin Pharmacological Effects of the Spin Trap Agents N-t-Butyl-Phenylnitrone (PBN) and 2,2,6,6-Tetramethylpiperidine-N-Oxyl (TEMPO) in a Rabbit Thromboembolic Stroke Model : Combination Studies With the Thrombolytic Tissue Plasminogen Activator Stroke, January 1, 2001; 32(1): 147 - 153. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1992 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |